ELDN — Eledon Pharmaceuticals Balance Sheet
0.000.00%
- $198.21m
- $58.03m
Annual balance sheet for Eledon Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 114 | 84.8 | 56.4 | 51.1 | 140 |
Net Total Receivables | 0.11 | 0 | — | — | — |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 116 | 88.3 | 59.5 | 56.1 | 144 |
Net Property, Plant And Equipment | 0.138 | 0.768 | 0.739 | 0.365 | 0.926 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 197 | 171 | 92.8 | 89.1 | 177 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Current Liabilities | 2.48 | 4.4 | 6.47 | 3.9 | 11.6 |
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 6.59 | 6.55 | 8.61 | 5.65 | 59.3 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 191 | 164 | 84.2 | 83.4 | 118 |
Total Liabilities & Shareholders' Equity | 197 | 171 | 92.8 | 89.1 | 177 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |